NCT02003209 2025-08-08Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNational Cancer Institute (NCI)Phase 3 Completed315 enrolled 11 charts